Ghanaian healthtech, mPharma, has appointed Kwesi Arhin as its new CEO. Arhin will be taking over from Gregory Rockson, Co-founder and former CEO, who spent 12 years in the role.

The new development, which took effect Monday, September 1, 2025, will see Arhin become mPharma’s leader after four years at the company.

“The company’s former CEO and Co-founder, Gregory Rockson, will be transitioning to the role of Chairman of the Board of Directors, ensuring a smooth and strategic handover. This transition comes at a critical time for mPharma, as we embrace opportunities to strengthen our impact,” the company said in a LinkedIn post.

Arhin joined mPharma in 2021 as the Global Head of Commercial, QRx, where he led the development and launch of the company’s franchise model in six African markets. The same year, he became Vice President of Retail, West Africa, overseeing business development, commercial budgeting, and performance management for the retail franchise business.

In 2023, Arhin became Senior Vice President, managing a team of 500 staff, supervising mPharma’s Nigeria retail business, and overseeing 270 franchise and company-owned retail pharmacies and health stores across 15 states in Nigeria.

Before becoming CEO in September, Arhin served as mPharma’s Chief Operating Officer (COO), a role he assumed in June 2025. Before joining mPharma, he was an assistant manager at PwC and a Business Intelligence Partner at Pernod Ricard.

He obtained his Bachelor of Science in Administration, Banking, and Finance from the University of Ghana Business School.

Following this appointment, Arhin becomes the second CEO in mPharma’s history and the first non-founder to serve in the position. As he succeeds Rockson, he steps in with big expectations to lead the company with a fresh perspective and build more sustainable models of healthcare delivery through mPharma’s business in Africa.

During Rockson’s tenure, mPharma grew from a small operation in Ghana to an pan-African operation across nine countries on the continent, acquired and bought stakes in healthcare businesses in Kenya, Uganda, and Nigeria, and raised $90 million in funding, including a $6.6 million Series A, a $9.7 million Series B, and a $35 million Series D. However, the company has faced its share of challenges, like in 2023 when it laid off 150 employees due to worsening economic conditions.